- Home
- NMG vs VNDA Comparison
NMG vs VNDA Comparison
Compare NMG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- VNDA
- Stock Information
- Founded
- NMG 2011
- VNDA 2002
- Country
- NMG Canada
- VNDA United States
- Employees
- NMG N/A
- VNDA N/A
- Industry
- NMG Other Metals and Minerals
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- VNDA Health Care
- Exchange
- NMG Nasdaq
- VNDA Nasdaq
- Market Cap
- NMG 245.1M
- VNDA 261.7M
- IPO Year
- NMG 2017
- VNDA 2006
- Fundamental
- Price
- NMG $1.71
- VNDA $4.55
- Analyst Decision
- NMG Strong Buy
- VNDA Strong Buy
- Analyst Count
- NMG 2
- VNDA 3
- Target Price
- NMG $2.58
- VNDA $15.33
- AVG Volume (30 Days)
- NMG 44.4K
- VNDA 370.7K
- Earning Date
- NMG 08-13-2025
- VNDA 07-30-2025
- Dividend Yield
- NMG N/A
- VNDA N/A
- EPS Growth
- NMG N/A
- VNDA N/A
- EPS
- NMG N/A
- VNDA N/A
- Revenue
- NMG N/A
- VNDA $201,351,000.00
- Revenue This Year
- NMG N/A
- VNDA $16.86
- Revenue Next Year
- NMG N/A
- VNDA $39.78
- P/E Ratio
- NMG N/A
- VNDA N/A
- Revenue Growth
- NMG N/A
- VNDA 13.37
- 52 Week Low
- NMG $1.22
- VNDA $3.81
- 52 Week High
- NMG $2.58
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- NMG 47.19
- VNDA 53.76
- Support Level
- NMG $1.70
- VNDA $4.49
- Resistance Level
- NMG $1.89
- VNDA $4.63
- Average True Range (ATR)
- NMG 0.07
- VNDA 0.14
- MACD
- NMG -0.01
- VNDA 0.00
- Stochastic Oscillator
- NMG 30.43
- VNDA 50.00
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.